However, several challenges to the implementation of informative FSHD clinical trials remain, including heterogeneity of muscle involvement, rarity of detectable DUX4 expression, a shortage of robust FSHD biomarkers, and relatively slow disease progression in adult patients. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.